The Role of Timing of Progression and Early Salvage Surgery in Unresectable Hepatocellular Carcinoma Treated with TACE Plus TKIs and PD-1 Inhibitors

被引:0
|
作者
Li, Xingzhi [1 ,2 ]
Tang, Zhihong [1 ]
Pang, Qingqing [1 ]
Wang, Xiaobo [1 ]
Bai, Tao [1 ]
Chen, Jie [1 ]
Wei, Meng [1 ]
Wei, Tao [1 ]
Li, Lequn [1 ]
Wu, Feixiang [1 ,3 ]
机构
[1] Guangxi Med Univ, Canc Hosp, Dept Hepatobiliary Surg, Nanning 530021, Peoples R China
[2] Nanchong Cent Hosp, Clin Coll 2, North Sichuan Med Coll, Dept Hepatobiliary Surg, Nanchong, Peoples R China
[3] Guangxi Med Univ, Key Lab Early Prevent & Treatment Reg High Frequen, Minist Educ, Nanning, Peoples R China
基金
中国国家自然科学基金;
关键词
Hepatocellular carcinoma; salvage surgery; early tumor progression; post-progression survival; real-world; CHEMOEMBOLIZATION; SURVIVAL;
D O I
10.2147/JHC.S481816
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The prognosis of initially unresectable hepatocellular carcinoma (iuHCC) has been improved by TACE with TKIs and PD-1 inhibitors (TTP). However, the role of timing of tumor progression and and early salvage surgery during TTP therapy remains unclear. Patients and Methods: The data of 151 patients who received TTP for iuHCC consecutively between November 2019 and December 2022 were retrospectively analyzed. The X-Tile software was used to determine the optimal threshold of progression timing to differentiate the post-progression survival (PPS) for patients with tumor progression, ultimately yielding 9 months as the optimal cut-off time. Early tumor progression was defined as patients with tumor recurrence (surgical patients) or progressive disease by mRECIST (nonsurgical patients) within 9 months of initial treatment. Accordingly, early salvage surgery was defined as salvage surgery performed within 9 months of the initial treatment. Results: Out of all the patients, 55 (36.4%) patients showed early tumor progression, 33 (34.4%) showed late tumor progression, and 63 (41.7%) showed non-progression. Patients who experienced early tumor progression had a median PPS of 5.2 months, while those with late tumor progression had a median PPS of 16.8 months (P < 0.001). Multivariable analysis revealed a robust independent correlation between early tumor progression and PPS (HR = 3.279, 95% CI: 1.591-6.756; P = 0.001). Patients who received early salvage surgery showed a considerably lower early tumor progression rate when compared with patients who did not receive early surgery (12.5% vs 42.9%, P = 0.002). The multivariable analysis revealed that early salvage surgery was an independent factor influencing early tumor progression (OR = 0.246; 95% CI: 0.078-0.773; P = 0.016). Conclusion: Early tumor progression is associated with worse PPS in patients with iuHCC receiving TTP therapy. Early salvage surgery can further improve patient outcomes by lowering the incidence of early progression.
引用
收藏
页码:1641 / 1652
页数:12
相关论文
共 50 条
  • [41] Pretreatment CT-based machine learning radiomics model predicts response in unresectable hepatocellular carcinoma treated with lenvatinib plus PD-1 inhibitors and interventional therapy
    Hua, Yonglin
    Sun, Zhixian
    Xiao, Yuxin
    Li, Huilong
    Ma, Xiaowu
    Luo, Xuan
    Tan, Wenliang
    Xie, Zhiqin
    Zhang, Ziyu
    Tang, Chenwei
    Zhuang, Hongkai
    Xu, Weikai
    Zhu, Haihong
    Chen, Yajin
    Shang, Changzhen
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2024, 12 (07) : 1 - 15
  • [42] Clinical efficacy of HAIC (FOLFOX) combined with lenvatinib plus PD-1 inhibitors vs. TACE combined with lenvatinib plus PD-1 inhibitors in the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombus and arterioportal fistulas
    Lin, Zhipeng
    Chen, Du
    Hu, Xiaolong
    Huang, Dabei
    Chen, Yuan
    Zhang, Jian
    Li, Xiaoqun
    Zou, Xugong
    AMERICAN JOURNAL OF CANCER RESEARCH, 2023, 13 (11): : 5455 - 5465
  • [43] PD-1 and PD-L1 Inhibitors as Salvage Therapy for Urothelial Carcinoma
    Sonpavde, Guru
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (11): : 1073 - 1074
  • [44] Peripheral Th and NK cells are associated with response to lenvatinib plus PD-1 inhibitor in unresectable hepatocellular carcinoma
    Zou, Yiping
    Chen, Zhihong
    Chen, Zhenrong
    Zhang, Yuanpeng
    Zheng, Zehao
    Wu, Fan
    Xu, Lianqun
    Li, Qiao
    Lin, Ye
    Shi, Ning
    Jin, Haosheng
    CLINICAL IMMUNOLOGY, 2023, 249
  • [45] Feasibility and Tolerability of Lenvatinib, Plus PD-1 Blockades for Patients with Unresectable Hepatocellular Carcinoma: A Retrospective Exploratory Study
    Jia, Meng
    Jia, Jiang-Kun
    Xu, Jian
    Xue, Huan-Zhou
    CANCER MANAGEMENT AND RESEARCH, 2022, 14 : 2625 - 2638
  • [46] Lenvatinib plus PD-1 inhibitors in 378 unresectable hepatocellular carcinoma: A large real-world study from two centers.
    Yang, Xu
    Chen, Bowen
    Wang, Yanyu
    Wang, Yunchao
    Long, Junyu
    Zhang, Nan
    Xue, Jinnan
    Xun, Ziyu
    Zhang, Linzhi
    Cheng, Jiamin
    Lei, Jin
    Pan, Jie
    Hu, Ke
    Guan, Mei
    Huo, Li
    Mao, Yilei
    Sang, Xinting
    Lu, Yinying
    Zhao, Hai-Tao
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16155 - E16155
  • [47] Tyrosine kinase inhibitors (TKIs) plus transarterial chemoembolization (TACE) compared to TACE alone as downstaging therapy in transplant recipients with hepatocellular carcinoma
    Esmail, A.
    Kodali, S.
    Graviss, E.
    Nguyen, D.
    Moore, L.
    Saharia, A.
    Uosef, A.
    Victor, D.
    Abdelrahim, M.
    ANNALS OF ONCOLOGY, 2022, 33 : S308 - S308
  • [48] Pretreatment CT-based machine learning radiomics model to predict response in unresectable hepatocellular carcinoma treated with lenvatinib plus PD-1 inhibitors and interventional therapy.
    Shang, Changzhen
    Hua, Yonglin
    Chen, Yajin
    Zhuang, Hongkai
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (23_SUPPL) : 94 - 94
  • [49] Efficacy of Lenvatinib Combined with PD-1 Inhibitor versus Sorafenib and PD-1 Inhibitor with or Without TACE for Hepatocellular Carcinoma with
    Duan, Wen-Bin
    Wang, Xiao-Hui
    Zhang, Guo-Can
    He, Zhuo
    Li, Shao-Qiang
    Zhou, Jie
    IMMUNOTARGETS AND THERAPY, 2024, 13 : 247 - 258
  • [50] Real-World Effectiveness of Sorafenib versus Lenvatinib Combined with PD-1 Inhibitors in Unresectable Hepatocellular Carcinoma
    Chiang, Hsueh-Chien
    Lee, Yang-Cheng
    Chang, Ting-Tsung
    Lin, Yih-Jyh
    Wu, Hung-Tsung
    Wang, Chung-Teng
    Chen, Chiung-Yu
    Chen, Po-Jun
    Hsieh, Ming-Tsung
    Lin, Sheng-Hsiang
    Chen, Shang-Hung
    Chuang, Chiao-Hsiung
    Wu, I-Chin
    Hong, Tzu-Chun
    Wu, Juei-Seng
    Han, Meng-Zhi
    Chen, Wei-Ting
    Chiang, Chien-Ming
    Hung, Kuan-Kai
    Kuo, Hsin-Yu
    CANCERS, 2023, 15 (03)